• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Zevra Therapeutics Inc.

    2/12/25 9:32:25 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVRA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Zevra Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    488445206

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    488445206


    1Names of Reporting Persons

    Adage Capital Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,650,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,650,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,650,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.84 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    488445206


    1Names of Reporting Persons

    Robert Atchinson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,650,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,650,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,650,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.84 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    488445206


    1Names of Reporting Persons

    Phillip Gross
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,650,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,650,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,650,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.84 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Zevra Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    1180 Celebration Boulevard, Suite 103, Celebration, FL 34747
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Adage Capital Management, L.P., a Delaware limited partnership ("ACM"), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership ("ACP"), with respect to the shares of common stock, par value $$0.0001 per share ("Common Stock") of Zevra Therapeutics, Inc., a Delaware corporation (the "Company") directly held by ACP; (ii) Robert Atchinson ("Mr. Atchinson"), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company ("ACPLLC"), general partner of ACM, with respect to the shares of Common Stock directly held by ACP; and (iii) Phillip Gross ("Mr. Gross"), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock directly held by ACP. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
    (c)Citizenship:

    ACM is a limited partnership organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    488445206
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 53,375,932 shares of Common Stock outstanding as of November 8, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the Securities and Exchange Commission on November 13, 2024.
    (b)Percent of class:

    6.84  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a).
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Adage Capital Management, L.P.
     
    Signature:/s/ Robert Atchinson
    Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
    Date:02/12/2025
     
    Robert Atchinson
     
    Signature:/s/ Robert Atchinson
    Name/Title:Robert Atchinson, individually
    Date:02/12/2025
     
    Phillip Gross
     
    Signature:/s/ Phillip Gross
    Name/Title:Phillip Gross, individually
    Date:02/12/2025
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement

    Get the next $ZVRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZVRA

    DatePrice TargetRatingAnalyst
    7/2/2025$26.00Buy
    H.C. Wainwright
    1/8/2025$25.00Overweight
    Cantor Fitzgerald
    10/7/2024$20.00Buy
    Guggenheim
    9/24/2024$17.00Mkt Outperform
    JMP Securities
    9/24/2024$18.00 → $25.00Buy
    Maxim Group
    4/2/2024$12.00 → $18.00Buy
    Maxim Group
    3/12/2024Outperform
    William Blair
    3/17/2023$12.00Buy
    Maxim Group
    More analyst ratings

    $ZVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Mcfarlane Neil F. converted options into 37,500 shares and sold $125,186 worth of shares (14,625 units at $8.56), increasing direct ownership by 6% to 387,225 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/10/26 4:49:28 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Finance & Corp Controller Sangiovanni Timothy J. sold $27,548 worth of shares (3,000 units at $9.18), decreasing direct ownership by 9% to 29,590 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/4/26 4:27:22 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CCO Schafer Joshua sold $96,500 worth of shares (10,500 units at $9.19), decreasing direct ownership by 14% to 62,278 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/4/26 4:27:11 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

    CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the presentation of four posters highlighting positive new data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™. "These data highlight MIPLYFFA's potential to meaningfully stabilize disease progression across a broad spectrum of NPC patients, including adults who have historically had limited clinical data," said Adrian Quartel, M.D., FFPM, Zevra's Chief Medical Officer. "As controlled clinical tr

    2/4/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

    CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has been invited to ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, Zevra's President and Chief Executive Officer, will deliver opening remarks at 9:24 a.m. followed by the bell ringing at 9:30 a.m. ET, signifying the start of the day's trading session. The opening bell ceremony can be seen live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony and on the Nasdaq MarketSite Tower at 43rd and Broadway in New York, NY. Ab

    2/2/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™

    Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD Company to host satellite symposium on diagnostic and therapeutic advances in Niemann-Pick disease type C (NPC) CELEBRATION, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that four abstracts discussing data and clinical experience associated with MIPLYFFA® (arimoclomol) have been accepted for presentation at the 22nd Annual WORLDSymposium™. Dr. Caroline Hastin

    1/26/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Favorito Tamara A bought $24,718 worth of shares (3,175 units at $7.79), increasing direct ownership by 442% to 3,894 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    9/16/25 4:15:37 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Shih Alvin bought $157,800 worth of shares (20,000 units at $7.89) (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    9/15/25 4:07:29 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bode John B bought $45,825 worth of shares (5,000 units at $9.16), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    8/20/25 4:38:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Zevra Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $26.00

    7/2/25 7:59:19 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Zevra Therapeutics with a new price target

    Cantor Fitzgerald resumed coverage of Zevra Therapeutics with a rating of Overweight and set a new price target of $25.00

    1/8/25 8:49:26 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Zevra Therapeutics with a new price target

    Guggenheim initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $20.00

    10/7/24 8:28:23 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    SEC Filings

    View All

    Zevra Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    12/17/25 4:15:39 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    12/2/25 7:34:13 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    11/20/25 4:29:38 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Financials

    Live finance-specific insights

    View All

    Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

    2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the three and nine months ended September 30, 2025. "Zevra is well-positioned for continued growth, driven by the strong performance of MIPLYFFA and the meaningful impact we are delivering to patients with Niemann-Pick disease type C," said Neil F.

    11/5/25 4:05:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

    CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the third quarter 2025 on Wednesday, November 5, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at investors.zevra.com. To join via telephone, please use the following dial-in information: (800) 579-2543 (

    10/27/25 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

    Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial launches and development programs Submitted a Marketing Authorisation Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C Company to host conference call and webcast TODAY, August 12, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, t

    8/12/25 4:05:19 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zevra Therapeutics Inc.

    SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/14/24 1:00:16 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

    SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/12/24 5:59:21 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

    SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/4/24 2:15:20 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Leadership Updates

    Live Leadership Updates

    View All

    Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

    CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alicia Secor to the Company's Board of Directors (Board). The Company also announced the retirement of director Wendy Dixon, PhD, effective today. "We are pleased to welcome Alicia to our Board at this important juncture, as her expertise will support our continued execution of strategy and our commitment to delivering durable, sustained value for shareholders," said Tamara A. Favorito, Zevra's Chair of the Board. "We sincerely appreciate Wendy's

    12/2/25 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

    Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company's Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan CELEBRATION, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) ("Zevra," or the "Company"), a commercial-stage company focused on providing therapies to people living with rare disease, announced that based on the final vote count certified by the independent Inspector of Elections following the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"), stockholders have voted to re-elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the

    5/29/25 4:35:32 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Expands Executive Leadership Team

    Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointments of Rahsaan W. Thompson as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer. Both Mr. Thompson and Ms. Peters bring deep expertise in building high-performing teams which will be essential to deliver success through the Company's next phase of growth. "We are thrilled to welcome both Rahsaan and Alison to the Zevra team as w

    6/25/24 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care